Vanguard Group
VRCA icon

Vanguard Group’s Verrica Pharmaceuticals VRCA Stock Holding History

Vanguard Group’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$1.15M Sell
138,194
-87,016
-39% -$482K ﹤0.01% 3738
2025
Q3 		$971K Buy
225,210
+8,379
+4% +$50.5K ﹤0.01% 3796
2025
Q2 		$1.15M Sell
216,831
-19,301
-8% -$104K ﹤0.01% 3705
2025
Q1 		$1.04M Buy
236,132
+48,141
+26% +$311K ﹤0.01% 3697
2024
Q4 		$1.32M Buy
187,991
+59,331
+46% +$652K ﹤0.01% 3677
2024
Q3 		$1.87M Buy
128,660
+1,713
+1% +$77.1K ﹤0.01% 3577
2024
Q2 		$9.25M Buy
126,947
+76
+0.1% +$5.84K ﹤0.01% 2978
2024
Q1 		$7.51M Buy
126,871
+761
+0.6% +$42K ﹤0.01% 3119
2023
Q4 		$9.23M Buy
126,110
+3,424
+3% +$141K ﹤0.01% 2987
2023
Q3 		$4.77M Buy
122,686
+242
+0.2% +$12.3K ﹤0.01% 3271
2023
Q2 		$7.07M Buy
122,444
+10,666
+10% +$648K ﹤0.01% 3138
2023
Q1 		$7.27M Buy
111,778
+9,499
+9% +$575K ﹤0.01% 3125
2022
Q4 		$2.81M Buy
102,279
+1,019
+1% +$27.2K ﹤0.01% 3539
2022
Q3 		$2.96M Hold
101,260
– – ﹤0.01% 3593
2022
Q2 		$1.95M Buy
101,260
+32,044
+46% +$1.61M ﹤0.01% 3819
2022
Q1 		$5.61M Sell
69,216
-4
-0% -$330 ﹤0.01% 3472
2021
Q4 		$6.34M Buy
69,220
+2
+0% +$227 ﹤0.01% 3482
2021
Q3 		$8.65M Buy
69,218
+437
+0.6% +$49K ﹤0.01% 3334
2021
Q2 		$7.77M Sell
68,781
-2,287
-3% -$277K ﹤0.01% 3342
2021
Q1 		$10.8M Buy
71,068
+11,503
+19% +$1.59M ﹤0.01% 3103
2020
Q4 		$6.86M Buy
59,565
+931
+2% +$85.6K ﹤0.01% 3189
2020
Q3 		$4.54M Sell
58,634
-916
-2% -$75K ﹤0.01% 3198
2020
Q2 		$6.56M Buy
59,550
+1,601
+3% +$185K ﹤0.01% 2973
2020
Q1 		$6.33M Buy
57,949
+705
+1% +$92.8K ﹤0.01% 2848
2019
Q4 		$9.1M Buy
57,244
+2,880
+5% +$425K ﹤0.01% 2903
2019
Q3 		$8.02M Buy
54,364
+8,654
+19% +$964K ﹤0.01% 2928
2019
Q2 		$5.31M Buy
45,710
+2,585
+6% +$242K ﹤0.01% 3147
2019
Q1 		$4.66M Buy
43,125
+2,601
+6% +$300K ﹤0.01% 3165
2018
Q4 		$3.3M Buy
40,524
+11,275
+39% +$1.37M ﹤0.01% 3222
2018
Q3 		$4.75M Buy
29,249
+26,465
+951% +$4.52M ﹤0.01% 3257
2018
Q2 		$549K Buy
+2,784
New +$545K ﹤0.01% 3807

Other funds holding VRCA

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $174M AUM
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Group's VRCA Position: Q4 2025 in Review

Vanguard Group reduced its Verrica Pharmaceuticals (VRCA) stake by 39% in Q4 2025, selling an estimated $482K and leaving 138,194 shares worth $1.15M. The position accounts for ﹤0.01% of the portfolio, ranked #3738.

Vanguard Group first reported a position in VRCA in Q2 2018 and has held it in 31 quarters since. The position peaked at $10.8M in Q1 2021. 50 funds tracked by Wall St. Rank hold VRCA as of Q4 2025.

  • Vanguard Group held 138,194 shares of Verrica Pharmaceuticals worth $1.15M as of Q4 2025.
  • Vanguard Group sold 87,016 Verrica Pharmaceuticals shares in Q4 2025, an estimated $482K.
  • Verrica Pharmaceuticals made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3738 holding.
  • Vanguard Group first reported a position in Verrica Pharmaceuticals in Q2 2018 and has held it in 31 quarters since.
  • Vanguard Group's Verrica Pharmaceuticals position peaked at $10.8M in Q1 2021.
  • 50 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.